Table 3.

Clinical activity

Overall response
Patients,nPR (%)PR unconfirmedPR confirmedSDa (%)Not assessable for SDPD (%)CBRb (%)
Melanoma, BRAF V600 mutatedc174 (24)135 (29)08 (47)9 (53)
 Previous BRAF inhibitor2002 (100)
Melanoma, non-BRAF V600 mutated204 (20)134 (20)111 (55)8 (40)
 NRAS81(13)012 (25)05 (62)3 (38)
 Non-NRAS102 (20)112 (20)15 (50)4 (40)
 NRAS unknown21 (50)01001 (50)1 (50)
NSCLC, KRAS mutatedd182 (11)028 (44)08 (44)10 (56)
Colorectal cancer, KRAS mutated250000124 (100)0
 KRASe140000014 (100)0
 KRAS/PIK3CA7000007 (100)0
 KRAS mutated/PIK3CA status unknown4000013 (100)0
  • aBest overall response of SD was defined as SD lasting ≥16 weeks for melanoma/colorectal cancer and ≥8 weeks for NSCLC.

  • bDefined as CR, PR, and SD.

  • cInclusive BRAF V600/CDK, BRAF V600/RET, BRAF V600/EGFR, BRAF V600/MET.

  • dInclusive KRAS/AKT1.

  • eInclusive KRAS/CDK and KRAS/MET.